Goldman Sachs analyst Salveen Richter suspended the firm’s rating on Taysha Gene Therapies saying it has "insufficient information" on which to base an investment view.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TSHA:
- Taysha Gene Therapies price target lowered to $4 from $15 at Truist
- Taysha Gene Therapies price target lowered to $6 from $16 at Chardan
- Taysha Gene Therapies price target lowered to $6 from $16 at Needham
- Taysha Gene Therapies downgraded to Hold at Jefferies on lead asset uncertainty
- Taysha Gene Therapies price target lowered to $13 from $17 at Canaccord
